Loading
companiesCompany
Wayshine Biopharm
Wayshine Biopharm is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the brain-penetrant EGFR inhibitor WSD0922-FU in non-small-cell lung cancer and small-cell lung cancer.
Also called: Wayshine Biopharm, Inc.
Overview
Wayshine Biopharm develops small-molecule targeted cancer drugs able to cross the blood-brain barrier, with a focus on brain tumours and lung cancer. Its lead product WSD0922-FU is an EGFR and EGFRvIII inhibitor in trials for EGFR-mutant non-small-cell lung cancer and glioma in China and the United States. The group parent is registered in the United States and the operating headquarters is in Shanghai. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06631989 (phase 1/2, A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advance...), NCT06868485 (phase 2, A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small...) and NCT07206498 (phase 1/2, A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#114of 1244 companies, score 47
- approved products +6
- targets +2
- modalities +2
- regions +7
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 231 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso
Osimertinib (Tagrisso) is the standard pill for EGFR-mutant lung cancer, now also given after surgery and with chemotherapy or after chemoradiation.
Similar pages
- TrialA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
cancers
drugs
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso
trials
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung CancerA Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung CancerA Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC